Zacks Investment Research upgraded shares of Pure Bioscience, Inc. (PURE) from NEUTRAL to OUTPERFORM on October 28, 2013, with a target price of $2.50.
PURE develops and markets SDC-based antimicrobial products that provide non-toxic solutions to numerous global health challenges. SDC is a novel, patented platform technology with superior efficacy and low toxicity and can be used in diverse markets including food safety, personal care, preservatives, industrials, agriculture and pharmaceuticals. After recent massive management change, PURE is refocusing on the food safety industry. We expect growth will resume in fiscal 2014, and upgrade its shares to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Pure Bioscience, Inc. (PURE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment